Professor Oliver Bandmann
MD, PhD
Neuroscience, School of Medicine and Population Health
Professor of Movement Disorders Neurology
Honorary Consultant Neurologist
Co-Director, Neuroscience Institute
+44 114 222 2237
Full contact details
Neuroscience, School of Medicine and Population Health
Room B32
91直播 Institute for Translational Neuroscience (SITraN)
385a Glossop Road
91直播
S10 2HQ
- Profile
-
- 2002-present: University of 91直播/Royal Hallamshire Hospital, 91直播, UK
- 1997-2002: Specialist Training in Neurology, Marburg, Germany;
- 1993-1997: Research Fellow, Institute of Neurology. Queen Square London. PhD on "Genetic Aspects of Parkinsonian Disorders" (Supervisors: Prof A.E. Harding, Prof C.D. Marsden, Prof N.W. Wood)
- 1992-1993: House officer, Dept Neurology, Klinikum Grosshadern, Munich (Head: Prof T. Brandt)
- 1991: Qualification at Ludwig Maximilian麓s University Munich, Germany
- Research interests
-
My research focuses on movement disorders, in particular Parkinson麓s Disease (PD) but also Huntington麓s Disease, Wilson Disease and dystonia. I鈥檓 particularly interested in working towards disease-modifying therapy for PD which would slow down disease progression.
The main areas of research within my group are as follows:
1. Mitochondrial dysfunction and compound screen with identification of neuroprotective compounds as candidates for disease-modifying treatment in Parkinson鈥檚 Disease:
We were the first group worldwide to undertake detailed assessment of mitochondrial function and morphology in both and . We subsequently undertook the mutant patient tissue. 2000 drugs were assessed for their rescue effect on mitochondrial function. A clear mode of action (MOA) was identified for a group of compounds which includes the FDA-licensed drug ursodeoxycholic acid (UDCA).For interested members of the public: Please have a look at the official for more information on this project. You may also be interested in listening to a .
Fig1. The image shows a fibroblast from a patient with Parkinson鈥檚 Disease due to mutations in the parkin gene. The fibroblast has been stained to show the mitochondria in the cell. We see increased branching and interconnectedness of the mitochondrial network in the fibroblasts from patients with parkin mutations compared to controls; this change in morphology of the mitochondria correlates with changes in function.
2. Bench to bedside 鈥 early clinical trials in Parkinson鈥檚 disease
There is emerging evidence of a 鈥淧arkinson Epidemic鈥 with a predicted global doubling in the number of people with Parkinson鈥檚 from 6 million to 12 million between 2015 and 2014 (PMID:30584159).
We have now taken UDCA as the top hit of our drug screen into an early clinical trial, called the UP study (short for: UDCA in Parkinson鈥檚 disease). The UP study will predominantly focus on investigating the safety and tolerability of UDCA in PD. However, we will also use novel techniques (in particular 31P-MR-Spectroscopy and sensor-based objective quantification of motor impairment) to gain some insight into the neuroprotective potential of UDCA.
MR Spectroscopy of a human brain with focussed analysis of the basal ganglia (the area most affected in Parkinson鈥檚 disease)
My group is also participating in two other multicentre neuroprotection trials, testing statins and antibodies against alpha-synuclein for their neuroprotective effect.
For interested members of the public: Please have a look at the official University of 91直播 Press release for more information on this project
/news/nr/liver-drug-trialled-in-parkinsons-patients-1.828628This link will take you to a webpage of the Cure Parkinson鈥檚 Trust - it provides additional information on UDCA for Parkinson鈥檚:
You may also find this video interesting during which we describe our journey from the bench at SITraN to the clinical trial carried out at the NIHR-funded Clinical Research facility at the Royal Hallamshire Hospital:
3. Zebrafish as a new vertebrate animal model for Parkinson鈥檚 Disease:
We were the first group worldwide to establish a at Bateson Centre of the University of 91直播 (/bateson).
We subsequently demonstrated that Parkin-deficient zebrafish share key features with human parkin-mutant Parkinson鈥檚 Disease patients, namely . Most recently, we have identified as novel mechanism leading to mitochondrial dysfunction and dopaminergic cell loss in PINK1 deficiency. Inhibition of TIGAR prevents loss of dopaminergic neurons by normalizing mitochondrial function. TIGAR is therefore a promising novel target for disease-modifying therapy in early onset Parkinson鈥檚 Disease. We are now also using zebrafish to study genetic risk factors for sporadic Parkinson鈥檚 and how they may interact with ageing.
For interested members of the public: Please have a look at the
official University of 91直播 press release for more information on this project.4. Mitochondrial biomarkers in Parkinson鈥檚 Disease:
We have just completed a detailed assessment of mitochondrial and lysosomal dysfunction in patients with sporadic Parkinson鈥檚 Disease. This will hopefully allow to eventually identify those patients with Parkinson鈥檚 Disease who are most likely to benefit from medication with mitochondrial rescue drugs.5. Huntington's Disease (HD)
We are recruiting patients for the Enroll-HD study at our multidisciplinary Huntington鈥檚 Disease clinic. As part of this, we have been frequently recruiting patients for HD drug trials and other HD studies.6. Wilson Disease (WD)
I have previously contributed to the development of the . More recently, we have conducted the first study on the genetic prevalence of Wilson Disease in the UK in collaboration with the Welcome Sanger Institute, Cambridge, UK. This study demonstrated a surprisingly high ATP7B carrier frequency which suggests that WD may be considerably more common than previously thought. In collaboration with the 91直播 Diagnostic Genetics Service, we also identified .In close collaboration with the Wilson disease patient self-help group, we have helped to establish a UK-wide, interdisciplinary Wilson disease network. This network will hopefully allow us to develop national standards for the care of Wilson disease patients and facilitate future research projects.
- Publications
-
Journal articles
- . Journal of Parkinson's Disease, 13(6), 851-864.
- . Journal of Parkinson's Disease, 13(6), 1011-1033.
- . Nature Reviews Drug Discovery, 22(9), 681-682.
- . Biomolecules, 13(1).
- . Bone, 168, 116651-116651.
- . Journal of Neurology, Neurosurgery & Psychiatry, 93(9), e2.2-e2.2.
- . The Lancet Gastroenterology & Hepatology.
- . The Lancet Neurology, 20(7), 559-572.
- . Neuroscience & Biobehavioral Reviews.
- . Cortex.
- . Scientific Reports, 11(1).
- . Neural Regeneration Research, 16(3), 500-500.
- . Movement Disorders, 36(2), 503-508.
- . Neuron, 109(3), 448-460.e4.
- . BMJ Open, 10(8).
- . Neurology, 94(21), 907-908.
- . Progress in Neurobiology, 187, 101772-101772.
- . Neurology: Clinical Practice, 10(1), 40-46.
- . Journal of Neurology Neurosurgery & Psychiatry, 90(12), e38.
- . Brain, 1-20.
- . Biology Open, 8(10).
- . Movement Disorders, 34(9), 1307-1314.
- . Neurobiology of Disease, 127, 563-569.
- . Value in Health, 22(6), 712-720.
- . Journal of Huntington's Disease, 8(2), 181-193.
- . American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 180(3), 232-245.
- . Nature Scientific Reports, 9.
- . Brain Research, 1706, 218-223.
- . Parkinsonism & Related Disorders, 61, 101-105.
- . Journal of Cerebral Blood Flow and Metabolism.
- . Journal of Molecular Biology, 430(21), 3942-3953.
- . Cell Reports, 23(10), 2976-2988.
- . Journal of Movement Disorders, 11(2), 53-64.
- . EJNMMI Research, 8(1).
- . Practical Neurology, 18(5), 352-358.
- . FEBS Letters, 592(5), 776-792.
- . Journal of Neurochemistry, 146(4), 356-373.
- . Nuclear Medicine Communications, 39(3), 268-275.
- . Journal of Huntington's Disease, 7(3), 209-222.
- . Journal of Neurology, Neurosurgery & Psychiatry, 88(Suppl 1), A31.4-A32.
- . Cortex, 95, 51-62.
- . The Lancet Neurology, 16(9), 701-711.
- . Sleep, 40(8).
- . Brain Sciences, 7(7).
- . Alzheimer's & Dementia, 13(7S_Part_26), P1269-P1269.
- . Handb Clin Neurol, 142, 7-17.
- . European Journal of Neuroscience, 45(4), 528-535.
- . Neurology.
- . Neuroscience Letters, 630, 23-29.
- . Human Molecular Genetics, 24(23), 6640-6652.
- . Neurology, 85(10), 846-852.
- . Neurology, 84(14_supplement).
- . The Lancet Neurology, 14(1), 103-113.
- . ACS Nano, 8(5), 4650-4661.
- . Neurology, 82(10_supplement).
- . Neurology, 82(10_supplement).
- . Neurogenetics, 15(1), 19-21.
- . J Neurol Neurosurg Psychiatry, 84(11), e2.
- . Journal of Affective Disorders, 151(1), 248-258.
- . Brain, 136(Pt 10), 3038-3050.
- . Ann Neurol, 74(6), 837-847.
- . Neurology, 81(9), 808-811.
- . PLoS ONE, 8(7).
- . Neurology, 80(19), 1740-1745.
- . Pract Neurol, 13(2), 114-119.
- . J Huntingtons Dis, 2(1), 107-124.
- . Brain, 136(Pt 5), 1476-1487.
- . Neurology, 80(7), 608-609.
- . Journal of Huntington's Disease, 2(1), 107-124.
- . Front Cell Neurosci, 7, 178.
- . Neurosci Lett, 532, 55-58.
- . Neurology, 78(10), 690-695.
- . Neurology, 78(11), 772-773.
- . PLoS Curr, 4, e4f8606b742ef3.
- . European Journal of Human Genetics, 20(1), 20-26.
- Prolonged generalized dystonia after chronic cerebellar application of kainic acid. Brain Research.
- . Brain Research, 1464, 82-88.
- . Journal of Neurology, Neurosurgery & Psychiatry, 82(12), 1409-1412.
- . Zebrafish, 8(3), 103-108.
- . Neurology, 75(22), 2017-2020.
- . Neurobiol Dis, 40(1), 58-65.
- . Hum Mol Genet, 19(R1), R21-R27.
- . AM J NEURORADIOL, 31(5), 856-861.
- . Neurology, 73(16), 1280-1285.
- . Nat Neurosci, 12(9), 1129-1135.
- . Brain, 132(Pt 6), 1613-1623.
- . Mitochondrion, 9(1), 63-63.
- . Ann Neurol, 64(5), 555-565.
- . J Neurochem, 106(5), 1991-1997.
- . Neurology, 71(8), 542-543.
- . Eur J Neurol, 15(7), 749-753.
- . Neurology, 70(16 Pt 2), 1375-1376.
- . Mov Disord, 23(1), 54-62.
- . J Neurochem, 100(6), 1626-1635.
- Unified Wilson's Disease Rating Scale (UWDRS) - a proposal for the neurological scoring of Wilson's disease patients. PARKINSONISM RELAT D, 13, S80-S80.
- Unified Wilson's Disease Rating Scale - a proposal for the neurological scoring of Wilson's disease patients.. Neurol Neurochir Pol, 41(1), 1-12.
- . Neurology, 67(12), 2250-2252.
- . Mov Disord, 21(10), 1789-1790.
- . Mov Disord, 21(6), 881-883.
- . Neurology, 66(6), 951-952.
- . Brain, 128(Pt 8), 1855-1860.
- . J Neurol Neurosurg Psychiatry, 76(8), 1058-1063.
- . Neurogenetics, 6(1), 55-56.
- . Mov Disord, 19(11), 1279-1284.
- Advances in dystonia. EUR J NEUROL, 11, 1-1.
- . Exp Neurol, 187(1), 199-202.
- . Neurosci Lett, 359(3), 195-197.
- . Neurology, 62(3), 357-358.
- . Mov Disord, 19(2), 192-196.
- . Neurology, 61(8), 1097-1101.
- . Am J Med Genet B Neuropsychiatr Genet, 119B(1), 60-64.
- . Neurology, 60(4), 700-702.
- . Ann Neurol, 53(2), 278-279.
- Myoclonic encephalopathy caused by chronic bismuth abuse.. Epileptic Disord, 4(4), 229-233.
- . Neurology, 59(5), 782-783.
- Spectrum of mutations in the gene for epsilon-sarcoglycan (SGCE) in myoclonus-dystonia syndrome (MDS, DYT11). NEUROLOGY, 58(7), A17-A17.
- . J Neural Transm (Vienna), 109(4), 503-512.
- . Neuropediatrics, 33(1), 1-5.
- Detailed genotyping demonstrates association between the slow acetylator genotype for N-acetyltransferase 2 (NAT2) and familial Parkinson's disease.. Mov Disord, 15(1), 30-35.
- . Eur J Neurol, 6(5), 549-554.
- . J Neurol Neurosurg Psychiatry, 66(5), 665-667.
- . Dtsch Med Wochenschr, 124(8), 219-222.
- . J Neurol Neurosurg Psychiatry, 66(1), 86-89.
- . J Neural Transm Suppl, 56, 155-164.
- Toxins, genetics, and Parkinson's disease: the role of N-acetyltransferase 2.. Adv Neurol, 80, 199-204.
- . Ann Neurol, 44(4), 649-656.
- . Ann Neurol, 44(2), 270-273.
- Mental disorders in movement disorders. CURR OPIN PSYCHIATR, 11(3), 315-319.
- . Mov Disord, 13(2), 203-211.
- Acetylator genotype and Parkinson's disease - Reply. LANCET, 351(9096), 142-142.
- . Lancet, 351(9096), 141-142.
- Atypical presentations of dopa-responsive dystonia.. Adv Neurol, 78, 283-290.
- . Neurology, 49(6), 1598-1604.
- . Lancet, 350(9085), 1136-1139.
- . J Neurol Neurosurg Psychiatry, 63(3), 304-308.
- . J Neurol, 244(4), 262-265.
- . J Neurol Sci, 141(1-2), 27-32.
- . Neuroscience, 72(4), 877-879.
- . J Neurol Neurosurg Psychiatry, 60(5), 588.
- . Hum Mol Genet, 5(3), 403-406.
- . J Neurol Neurosurg Psychiatry, 60(1), 98-101.
- Peripheral markers in Parkinson's disease. An overview.. Adv Neurol, 69, 283-291.
- . J Neurol Neurosurg Psychiatry, 59(5), 557.
- . J Neurol Neurosurg Psychiatry, 59(1), 90-91.
- . Mov Disord, 10(3), 277-278.
- Epidemiological, genetic, pharmacological, kinesiological, nuclear medical (IBZM-SPECT), standard and functional MRI studies on Parkinson's disease and related disorders and economic evaluation of Parkinson's disease therapy--clinical projects in the BMFT-research program Munich: "Parkinson's disease and other basal ganglia disorders".. J Neural Transm Suppl, 46, 325-337.
- . Mol Cell Probes, 8(6), 519-525.
- . Headache, 33(8), 446-448.
- . J Neural Transm Park Dis Dement Sect, 5(2), 107-116.
- . npj Parkinson's Disease, 10(1).
- . Annals of Neurology.
- . Brain.
- . Nature Communications, 14(1).
- . Movement Disorders.
- . Disease Models & Mechanisms.
- . Brain.
- . Movement Disorders.
- . The Journal of Neuroscience.
- . Journal of Neurology, Neurosurgery & Psychiatry.
- . Brain.
- . Practical Neurology.
- . PLoS Currents, 3, RRN1247-RRN1247.
- . Neurology, 87(3), 247-248.
- The common PARK8 mutation LRRK2 G2019S is not a risk factor for breast cancer in the absence of Parkinson's disease.. Journal of Neurology.
Chapters
- , Neuroscience for Neurologists (pp. 181-200). PUBLISHED BY IMPERIAL COLLEGE PRESS AND DISTRIBUTED BY WORLD SCIENTIFIC PUBLISHING CO.
Conference proceedings papers
- . I: Experimental therapeutics 鈥 preclinical (pp A152.1-A152)
- Treatment Selection in Multi-Arm Multi-Stage Clinical Trials in Parkinson Disease: The Search for the Ideal Neuroprotective Drug. MOVEMENT DISORDERS, Vol. 37 (pp S329-S329)
- Multimodal mechanistic disease stratification in sporadic Parkinson's disease. MOVEMENT DISORDERS, Vol. 37 (pp S113-S113)
- Developing 31-phosphorus magnetic resonance spectroscopy (31P-MRS) as an imaging biomarker to identify mitochondrial dysfunction in Parkinson's disease. MOVEMENT DISORDERS, Vol. 36 (pp S370-S371)
- (31)Phosphorus Magnetic Resonance Spectroscopy as a Tool to Identify Mitochondrial Dysfunction in Parkinson's Disease In-Vivo. ANNALS OF NEUROLOGY, Vol. 90 (pp S152-S153)
- The UP study - Ursodeoxycholic acid (UDCA) as neuroprotective treatment for Parkinson's disease. MOVEMENT DISORDERS, Vol. 35 (pp S413-S414)
- Disease-modifying treatment in Parkinson's disease - opportunities and obstacles. FEBS OPEN BIO, Vol. 9 (pp 40-40)
- Adult neurogenesis is impaired in pink1-/- zebrafish (Danio rerio). MOVEMENT DISORDERS, Vol. 33 (pp S605-S605)
- Acid sphingomyelinase deficiency rescues mitochondrial dysfunction in gba-/- zebrafish (Danio rerio). MOVEMENT DISORDERS, Vol. 33 (pp S615-S615)
- Impact of Computer Aided Diagnosis (CAD) on DaTSCAN reporting: a pilot study. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, Vol. 44 (pp S611-S611)
- The role of TIGAR in Parkinson's disease. NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY, Vol. 42 (pp 34-35)
- . Journal of Neurology, Neurosurgery & Psychiatry, Vol. 86(11) (pp e4.93-e4)
- . Journal of Neurology, Neurosurgery & Psychiatry, Vol. 86(11) (pp e4.46-e4)
- . 2015 IEEE 12th International Symposium on Biomedical Imaging (ISBI), 16 April 2015 - 19 April 2015.
- . 2014 22nd International Conference on Pattern Recognition, 24 August 2014 - 28 August 2014.
- TIGAR inactivation rescues dopaminergic neurons in parkin deficiency. MOVEMENT DISORDERS, Vol. 29(14) (pp 1839-1840)
- TIGAR inactivation rescues dopaminergic neurons in parkin deficiency. MOVEMENT DISORDERS, Vol. 29 (pp S3-S3)
- Neurodegeneration caused by intronic expansions of C9ORF72 is a clinically heterogeneous but pathologically distinct disease. LANCET, Vol. 381 (pp 32-32)
- . JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, Vol. 83
- Mitochondrial Impairment in Manifesting LRRK2-G2019S Carriers. NEUROLOGY, Vol. 74(9) (pp A255-A255)
- Bone marrow transplantation in adult cerebral X-linked adrenoleukodystrophy: an update. BONE MARROW TRANSPLANTATION, Vol. 43 (pp S182-S183)
- Complex I deficiency and dopaminergic neuronal cell loss in parkin-deficient zebrafish (Danio rerio). MOVEMENT DISORDERS, Vol. 24 (pp S135-S135)
- Abnormal mitochondrial function and morphology in fibroblasts of patients with early onset Parkinson's disease and two parkin mutations. NEUROLOGY, Vol. 70(11) (pp A485-A485)
- Mitochondrial function and morphology in parkin mutant fibroblasts. MOVEMENT DISORDERS, Vol. 23(1) (pp S49-S49)
- P53 dependent neuronal cell death in a DJ-1 deficient zebrafish model of Parkinson disease. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, Vol. 78(9) (pp 1024-1024)
- Proximal and central myelin damage of cranial nerves in hereditary neuropathy with liability to pressure palsies. NEUROLOGY, Vol. 64(6) (pp A376-A376)
- Immunocytological analysis of B-, T-, and natural killer cell subsets in Tourette syndrome. MOVEMENT DISORDERS, Vol. 19 (pp S439-S439)
- The Va166Met polymorphism of the brain derived neurotrophic factor (BDNF): A shared genetic risk factor for obsessive-compulsive behaviour and Gilles de la Tourette syndrome?. MOVEMENT DISORDERS, Vol. 19 (pp S354-S354)
- Prevalence of UCHL1, DJ1 and NR4A2 gene mutations in young-onset Parkinson's disease (YOPD) patients. MOVEMENT DISORDERS, Vol. 19 (pp S358-S358)
- The role of the epsilon-sarcoglycan gene (SGCE) in Gilles de la Tourette patients. MOVEMENT DISORDERS, Vol. 19 (pp S363-S363)
- Evaluation of the epsilon-sarcoglyan (SGCE) promoter region in myoclonus-dystonia (M-D). MOVEMENT DISORDERS, Vol. 19 (pp S96-S97)
- Gene expression studies in a novel rat dystonia model. MOVEMENT DISORDERS, Vol. 19 (pp S98-S98)
- The role of CNS dopaminergic, serotonergic and hypocretin (Orexin) systems in restless legs syndrome. SLEEP, Vol. 26 (pp A325-A326)
- Tourette syndrome and attention deficit hyperactivity disorder: Are there shared genetic susceptibility factors?. MOVEMENT DISORDERS, Vol. 17 (pp S342-S342)
- Dopamine receptor and hypocretin gene polymorphisms in Parkinson's disease (PD) patients reporting "sleep attacks". MOVEMENT DISORDERS, Vol. 17 (pp S138-S138)
- Candidate gene research in focal dystonia excludes involvement of ATP7A, ATP7B, ATOX, HLA-DR and MTHFR. MOVEMENT DISORDERS, Vol. 17 (pp S278-S279)
Preprints
- Research group
-
- Clinical Fellows: Dr Tom Payne, Dr Emily Reed
- UP study Trial Manager: Sarah Moll (co-funded by 91直播 Neuroscience BRC)
- Post-doctoral scientists: Dr Lisa Watson (ne Trollope), Dr Deepak Ailandi
- PhD students as primary supervisor: Mohammed Karami, Hannah Larbalestier, Emma White
Co-supervision with Dr Heather Mortiboys:
- Postdoctoral scientist: Dr Helen Rowland
- PhD students: Chris Hastings, Ruby McDonald, Rachel Hughes
- Technician: Sarah Roscoe
- Grants
-
The UP Study is predominantly funded by the JP Moulton Foundation, but also supported by Cure Parkinson鈥檚 UK and the 91直播 Neuroscience BRC.
My research is also supported by the Medical Research Council (MRC), the Michael J Fox Foundation (MJFF) and the University of 91直播. In the past, I鈥檝e also had substantial funding from Parkinson鈥檚 UK.
- Teaching interests
-
I was the Dept Neuroscience Undergraduate Teaching Lead/Director for Teaching and Learning for 15 years (2002-2017). I was also the University of 91直播 BMedSci Programme Director for 5 years (2013-2018).
I twice won the 鈥淐onsultant Teacher of the Year" award of the 91直播 Medical Student Society MedSoc.
I continue to contribute to all undergraduate phases of our MBChB course and also contribute to SITRaN-based MSc courses.
I am now the academic training lead for the STH Neuroscience Directorate and also the Training Lead for our NIHR-funded 91直播 Neuroscience BRC.
- Professional activities and memberships
-
- Member of the Editorial Board of the clinical Neuroscience Journals NEUROLOGY and Parkinsonism& Related Disorders
- Member of the MRC-DPFS Panel
- Deputy Chair of Association of British Neurologists (ABN) Research Committee
- Chair of the ABN Movement Disorders Advisory Group
- Movement Disorders Theme Lead of STH Academic Neuroscience Directorate and the NIHR-funded 91直播 Neuroscience BRC
Awards and esteem factors
- 1984-1991: Bavarian Scholarship for highly gifted students
- 1986-1991: German Scholarship for highly gifted students ("Studienstiftung des Deutschen Volkes")
- 1993-1997: Training Fellowship of Deutsche Forschungsgemeinschaft (DFG)
- 1996: Presidents Prize of Royal Society of Medicine
- 1997: Queen Square Prize of Institute of Neurology
- 2000: Oppenheim Prize of German Dystonia Society
- 2006: "Consultant Teacher of the Year" Prize of "Med Soc" (organization of medical students at UoS Medical School)